All In Biotech

Drug Trial Radar · NCT04879628

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

129

Actual

Start

Jun 7, 2021

Primary completion

Sep 21, 2022

Study completion Aug 23, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: * To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures * To evaluate the safety and tolerability of SAR441344 * To evaluate pharmacokinetics of SAR441344

Conditions

  • Multiple Sclerosis

Interventions

  • SAR441344 IVDrug

    Pharmaceutical form: Solution Route of administration: IV infusion

  • placebo IVDrug

    Pharmaceutical form: Solution Route of administration: IV infusion

  • SAR441344 SCDrug

    Pharmaceutical form: Solution Route of administration: SC injection

  • placebo SCDrug

    Pharmaceutical form: Solution Route of administration: SC injection

  • MRI contrast-enhancing preparationsDrug

    gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI)Time frame: Week 8 and Week 12

Locations

37 sites in 10 countries. Site status is shown where the registry gives one.

  • Center for Neurology and Spine- Site Number : 8400007

    Phoenix, Arizona

  • University of South Florida Site Number : 8400001

    Tampa, Florida

  • The Neurological Institute Site Number : 8400004

    Charlotte, North Carolina

  • Medical College of Wisconsin- Site Number : 8400006

    Milwaukee, Wisconsin

  • Investigational Site Number : 1000002

    Pleven, Bulgaria

  • Investigational Site Number : 1000003

    Sofia, Bulgaria

  • Investigational Site Number : 1000001

    Sofia, Bulgaria

  • Investigational Site Number : 1240001

    Gatineau, Quebec, Canada

  • Investigational Site Number : 2030003

    Brno, Czechia

  • Investigational Site Number : 2030002

    Hradec Králové, Czechia

  • Investigational Site Number : 2030001

    Jihlava, Czechia

  • Investigational Site Number : 2030005

    Ostrava - Poruba, Czechia

  • Investigational Site Number : 2030004

    Teplice, Czechia

  • Investigational Site Number : 2500006

    Calais, France

  • Investigational Site Number : 2760012

    Leipzig, Germany

  • Investigational Site Number : 2760004

    Münster, Germany

  • Investigational Site Number : 6430002

    Kazan', Russia

  • Investigational Site Number : 6430007

    Moscow, Russia

  • Investigational Site Number : 6430006

    Moscow, Russia

  • Investigational Site Number : 6430001

    Moscow, Russia

  • Investigational Site Number : 6430003

    Saint Petersburg, Russia

  • Investigational Site Number : 6430005

    Saint Petersburg, Russia

  • Investigational Site Number : 6430004

    Saint Petersburg, Russia

  • Investigational Site Number : 6430008

    Tyumen, Russia

  • Investigational Site Number : 7240002

    Vigo, Spain

  • Investigational Site Number : 7240004

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7920004

    Eskişehir, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number : 7920001

    İzmit, Turkey (Türkiye)

  • Investigational Site Number : 7920002

    Mersin, Turkey (Türkiye)

  • Investigational Site Number : 8040010

    Dnipro, Ukraine

  • Investigational Site Number : 8040006

    Dnipro, Ukraine

  • Investigational Site Number : 8040008

    Ivano-Frankivsk, Ukraine

  • Investigational Site Number : 8040002

    Kyiv, Ukraine

  • Investigational Site Number : 8040004

    Lviv, Ukraine

  • Investigational Site Number : 8040003

    Odesa, Ukraine

  • Investigational Site Number : 8040005

    Vinnytsia, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.